Cargando…
GLI inhibitor GANT-61 diminishes embryonal and alveolar rhabdomyosarcoma growth by inhibiting Shh/AKT-mTOR axis
Rhabdomyosarcoma (RMS) typically arises from skeletal muscle. Currently, RMS in patients with recurrent and metastatic disease have no successful treatment. The molecular pathogenesis of RMS varies based on cancer sub-types. Some embryonal RMS but not other sub-types are driven by sonic hedgehog (Sh...
Autores principales: | Srivastava, Ritesh K., Kaylani, Samer Zaid, Edrees, Nayf, Li, Changzhao, Talwelkar, Sarang S., Xu, Jianmin, Palle, Komaraiah, Pressey, Joseph G., Athar, Mohammad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322980/ https://www.ncbi.nlm.nih.gov/pubmed/25432075 |
Ejemplares similares
-
GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment
por: Li, Jianlong, et al.
Publicado: (2016) -
Mode and specificity of binding of the small molecule GANT61 to GLI determines inhibition of GLI-DNA binding
por: Agyeman, Akwasi, et al.
Publicado: (2014) -
Inhibition of autophagy potentiates the efficacy of Gli inhibitor GANT-61 in MYCN-amplified neuroblastoma cells
por: Wang, Jing, et al.
Publicado: (2014) -
Targeting GLI by GANT61 involves mechanisms dependent on inhibition of both transcription and DNA licensing
por: Zhang, Ruowen, et al.
Publicado: (2016) -
Aberrant GLI1 Activation in DNA Damage Response, Carcinogenesis and Chemoresistance
por: Palle, Komaraiah, et al.
Publicado: (2015)